表3.
EGFR敏感突变人群中，影响PFS的单因素和多因素回归分析（n=141）
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | ||
| Gender | 0.523 | ||||
| Male | 1.121 (0.790-1.589) | ||||
| Female | |||||
| Age (yr) | 0.848 | ||||
| ≥65 | 0.967 (0.683-1.368) | ||||
| <65 | Reference | ||||
| Smoking | 0.810 | ||||
| Yes | 1.047 (0.721-1.521) | ||||
| No | Reference | ||||
| TP53 comutation | 0.987 | ||||
| Yes | 0.997 (0.648-1.532) | ||||
| No | Reference | ||||
| CEA level | 0.714 | ||||
| Elevated | 0.933 (0.644-1.352) | ||||
| Normal | Reference | ||||
| Morphology of cancer cell | |||||
| Acinar predominant | 0.961 (0.563-1.641) | 0.884 | |||
| Papillary/Micropapillary predominant | 1.070 (0.570-2.008) | 0.833 | |||
| Solid predominant | Reference | ||||
| EGFR mutation | 0.013 | 0.055 | |||
| 19del | 0.645 (0.455-0.913) | 0.708 (0.497-1.008) | |||
| L858R | Reference | Reference | |||
| Brain metastasis | 0.219 | ||||
| Yes | 1.307 (0.853-2.001) | ||||
| No | Reference | ||||
| PD-L1 expression | |||||
| TPS≥50% | 7.175 (4.331-11.886) | <0.001 | 7.08 (4.227-11.889) | <0.001 | |
| 1%≤TPS<50% | 1.236 (0.833-1.836) | 0.293 | 1.212 (0.814-1.804) | 0.344 | |
| TPS<1% | Reference | Reference | |||
| Treatment | 0.018 | 0.742 | |||
| EGFR-TKIs combination therapy | 0.621 (0.418-0.923) | 0.916 (0.543-1.544) | |||
| EGFR-TKIs monotherapy | Reference | Reference | |||
| Radiotherapy | 0.005 | 0.016 | |||
| Yes | 0.505 (0.312-0.816) | 0.522 (0.306-0.887) | |||
| No | Reference | Reference | |||